Privately held Incyte Pharmaceuticals Inc. of Palo Alto, Calif.,announced that it has extended its research collaboration withthe Mayo Foundation for Medical Education and Research.
The collaboration will use Incyte's large-scale cDNA and proteinsequencing capabilities to characterize novel eosinophil,basophil and mast cell proteins involved in inflammation andallergy, with particular focus on cytokines, receptors andregulatory proteins.
Incyte will provide research funds for an initial three-yearperiod and retains a worldwide exclusive license to technologyrelating to the three protein types developed in the laboratoryof Mayo Foundation researcher Gerald Gleich, who "willcontribute rare sources of inflammatory cells," the companysaid.
(c) 1997 American Health Consultants. All rights reserved.